21 assets in Neurodegenerative Disease

Therapeutic assets addressing Neurodegenerative Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atorvastatin Neurodegenerative Disease	Monash University	P4	BB (65)
Live Combined Bifidobacterium Neurodegenerative Disease	Beijing Friendship Hospital	P4	BB (65)
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules Neurodegenerative Disease	Beijing Friendship Hospital	P4	BB (65)
Pimavanserin Neurodegenerative Disease	Vanderbilt University Medical Center	P4	BB (64)
Dexasone Neurodegenerative Disease	Eli Lilly and Company	P3	B (60)
Donanemab Neurodegenerative Disease	Eli Lilly and Company	P3	B (60)
Nexiguran Ziclumeran Neurodegenerative Disease	Intellia Therapeutics	P3	B (60)
Allopregnan-3.Alpha.-Ol-20-One Neurodegenerative Disease	University of Arizona	P2	CCC (53)
Tocovid Suprabio Neurodegenerative Disease	National Neuroscience Institute	P2	CCC (53)
Latozinemab Neurodegenerative Disease	Alector Inc.	P3	CCC (50)
[18F]MC225 Neurodegenerative Disease	University Medical Center Groningen	P1/2	CCC (48)
Kamlanoflast Neurodegenerative Disease	Inflammasome Therapeutics	P1/2	CCC (48)
Pegipanermin Neurodegenerative Disease	Inmune Bio, Inc.	P2	CCC (48)
snp318 Neurodegenerative Disease	SciNeuro	P1	CC (47)
Fluoroethylnormemantine Neurodegenerative Disease	ReST Therapeutics	P1	CC (43)
Apigenine Neurodegenerative Disease	Jinnah Postgraduate Medical Centre	N/A	D (30)
Chamomile Neurodegenerative Disease	Jinnah Postgraduate Medical Centre	N/A	D (30)
Melatonin Neurodegenerative Disease	Saint Vincent's Hospital, Korea	N/A	D (30)
Saffron Neurodegenerative Disease	Jinnah Postgraduate Medical Centre	N/A	D (30)